Thrombotic thrombocytopenic purpura with severe neurological impairment: remission after Rituximab.
F
F
Magalini
A
A
Stella
M
M
Basaglia
R
R
Vescovini
M
M
Sassi
A
A
Maria Lombardi
P
P
Sansoni
D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use; D003244:Consciousness Disorders / Q000209:etiology*; D003937:Diagnosis, Differential; D004660:Encephalitis / Q000175:diagnosis; D004830:Epilepsy, Tonic-Clonic / Q000209:etiology*; D005242:Fecal Incontinence / Q000209:etiology; D006212:Hallucinations / Q000209:etiology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D010951:Plasma Exchange; D011697:Purpura, Thrombotic Thrombocytopenic / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D012074:Remission Induction; D000069283:Rituximab; D014549:Urinary Incontinence / Q000209:etiology; D014750:Vincristine / Q000627:therapeutic use
D058846:Antibodies, Monoclonal, Murine-Derived; D000927:Anticonvulsants; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000069283:Rituximab; D014750:Vincristine